December 15, 2022 —  Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients l

December 15, 2022 —  Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your heart, the smooth muscle cells that give the blood vessels strength and flexibility start to get bigger and multiply.

Cardiac PET Technologist Workshop

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS). 

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing the company’s groundbreaking research that led to promising novel drug candidates for cardiovas

December 14, 2022 —  Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of-its-kind, purpose built, focal pulsed field ablation (PFA) therapy integrated seamlessly with 3D mapping & navigation.  

Both teams will harness decades of experience in pioneering novel PFA and navigation product solutions in various medical therapy applications. 

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular Robotics, a dedicated business within the Advanced Therapies area of Siemens Healthineers. This brand unification is the final step of the company integration process that commenced in 2019 with the acquisition of Corindus by Siemens Healthineers.

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market. The series will be available for viewing beginning on Monday, November 28, 2022. 

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's 

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk factors, but researchers

Subscribe Now